FY23 revenue view is is based on sacral neuromodulation and Bulkamid revenue each growing 25% compared to FY22. Sees FY23 sacral neuromodulation revenue $277.5M and Bulkamid revenue $64.5M.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AXNX:
